Palisade Bio (PALI) Amortization of Deferred Charges (2013 - 2017)
Palisade Bio (PALI) reported Amortization of Deferred Charges of $12127.0 for Q2 2017, down 15.57% year-over-year from $14363.0 in Q2 2016, and down 74.55% quarter-over-quarter from $47654.0 in Q1 2017.
Palisade Bio (PALI) Amortization of Deferred Charges (2013 - 2017) Analysis & Trends
Palisade Bio (PALI) has 5 years of Amortization of Deferred Charges data on file, last reported at $12127.0 in Q2 2017.
- Amortization of Deferred Charges for Q2 2017 came in at $12127.0, down 15.57% year-over-year; the trailing twelve-month figure through Dec 2017 was $59781.0 (down 82.8% YoY), and the FY2017 annual result was $59781.0, down 82.8% from the prior year.
- Amortization of Deferred Charges slipped to $12127.0 in Q2 2017 per PALI's latest filing, from $47654.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $231381.0 in Q4 2013 and troughed at $12127.0 in Q2 2017.
- A 5-year average of $155644.9 and a median of $207350.5 in 2014 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2014 and 2016: Amortization of Deferred Charges soared 881.51% in 2014, then sank 93.42% in 2016.
- A 5-year view of Amortization of Deferred Charges shows it stood at $231381.0 in 2013, then decreased by 10.37% to $207388.0 in 2014, then rose by 3.88% to $215440.0 in 2015, then slumped by 70.29% to $63998.0 in 2016, then sank by 81.05% to $12127.0 in 2017.
- Business Quant data shows PALI's Amortization of Deferred Charges at $12127.0 in Q2 2017, $47654.0 in Q1 2017, and $63998.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Palisade Bio | 357.48 Mn | 227.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 12,127.00 |
| Jun 30, 2017 | 12,127.00 |
| Mar 31, 2017 | 47,654.00 |
| Mar 31, 2017 | 47,654.00 |
| Dec 31, 2016 | 63,998.00 |
| Dec 31, 2016 | 63,998.00 |
| Sep 30, 2016 | 79,668.00 |
| Sep 30, 2016 | 79,668.00 |
| Jun 30, 2016 | 14,363.00 |
| Jun 30, 2016 | 14,363.00 |
| Mar 31, 2016 | 189,462.00 |
| Mar 31, 2016 | 189,462.00 |
| Dec 31, 2015 | 215,440.00 |
| Dec 31, 2015 | 215,440.00 |
| Sep 30, 2015 | 221,494.00 |
| Sep 30, 2015 | 221,494.00 |
| Jun 30, 2015 | 218,414.00 |
| Jun 30, 2015 | 218,414.00 |
| Mar 31, 2015 | 215,182.00 |
| Mar 31, 2015 | 215,182.00 |